Lactulose and rifaximin combination therapy as first-line treatment for preventing recurrent overt hepatic encephalopathy: a retrospective observational study

Key Points

• Combination therapy effectively suppresses overt hepatic encephalopathy (OHE) recurrence compared to monotherapy.
• Findings indicate a significant reduction in recurrence rates with the two-drug combination.
• Retrospective observational study highlights the advantages of dual therapy for OHE management.
• Implication of improved first-line treatment strategy necessitates further validation in clinical settings.